Division of Environmental and Preventive Medicine, Department of Social Medicine, Faculty of Medicine, Tottori University, Tottori, 683-8503, Japan,
Environ Health Prev Med. 2010 Nov;15(6):392-7. doi: 10.1007/s12199-010-0157-y. Epub 2010 May 26.
The β3-Adrenergic receptor gene polymorphism Trp64Arg (ADRB3 Trp64Arg) may be associated with weight gain, especially in the East Asian populations. To date, however, the results of various investigations aimed at determining whether ADRB3 Trp64Arg has any effect on weight reduction after intervention have been inconsistent. The aim of this study was to assess the effect of ADRB3 Trp64Arg on weight reduction in a non-pharmacological intervention program.
Fifty-seven Japanese men (average age 48.1 ± 5.9 years) whose body mass index (BMI) was >23.0 kg/m(2) participated in an intervention program in which they were encouraged to exercise by walking with a pedometer for 12 weeks. The BMI was measured at the start of the intervention program and on weeks 4, 8, and 12 (end) of the intervention period. The reduction in the BMI (ΔBMI) was calculated as the BMI value obtained at each point in comparison to the baseline (initial) BMI. The participants were classified into two groups: Arg allele non-carriers (Trp/Trp) and Arg allele carriers (Trp/Arg or Arg/Arg), respectively.
Among the participants, 61.4% were Trp/Trp homozygous, 38.6% were Trp/Arg heterozygous, and 0.0% were Arg/Arg homozygous. There was no significant difference in the ΔBMI between Arg allele non-carriers and Arg allele carriers at week 4 [non-carrier mean ± standard deviation (SD) vs. carrier mean ± SD: 0.25 ± 0.43 vs. 0.24 ± 0.35, respectively; p = 0.954], week 8 (0.56 ± 0.68 vs. 0.58 ± 0.61, respectively; p = 0.913), and week 12 (0.70 ± 0.86 vs. 0.84 ± 0.80, respectively; p = 0.545).
Our results suggest that ADRB3 Trp64Arg does not influence BMI reduction after an exercise-based intervention program.
β3-肾上腺素能受体基因多态性 Trp64Arg（ADRB3 Trp64Arg）可能与体重增加有关，尤其是在东亚人群中。然而，迄今为止，旨在确定 ADRB3 Trp64Arg 是否对干预后的体重减轻有影响的各种研究结果并不一致。本研究旨在评估 ADRB3 Trp64Arg 在非药物干预计划中对体重减轻的影响。
57 名日本男性（平均年龄 48.1±5.9 岁），体重指数（BMI）>23.0kg/m2，参加了一项干预计划，该计划通过计步器步行鼓励他们锻炼 12 周。在干预计划开始时、第 4、8 和 12 周（结束）测量 BMI。BMI 的减少（ΔBMI）是通过将每个点的 BMI 值与基线（初始）BMI 进行比较计算得出的。参与者被分为两组：分别为 Arg 等位基因非携带者（Trp/Trp）和 Arg 等位基因携带者（Trp/Arg 或 Arg/Arg）。
在参与者中，61.4%为 Trp/Trp 纯合子，38.6%为 Trp/Arg 杂合子，0.0%为 Arg/Arg 纯合子。Arg 等位基因非携带者和携带者在第 4 周（非携带者平均±标准差[SD]与携带者平均±SD：0.25±0.43 与 0.24±0.35，分别；p=0.954）、第 8 周（0.56±0.68 与 0.58±0.61，分别；p=0.913）和第 12 周（0.70±0.86 与 0.84±0.80，分别；p=0.545）的ΔBMI 没有显著差异。
我们的结果表明，ADRB3 Trp64Arg 不会影响基于运动的干预计划后的 BMI 减轻。
